Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3680466)

Published in PLoS One on June 12, 2013

Authors

Andrew J Solomon1, William Hills, Zunqiu Chen, James Rosenbaum, Dennis Bourdette, Ruth Whitham

Author Affiliations

1: Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, Vermont, United States of America. andrew.solomon@uvm.edu

Articles cited by this

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48

Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57

Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29

Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28

Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) (2004) 2.54

The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology (2001) 2.15

Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology (1995) 2.07

Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler (2001) 1.49

Primary Sjögren's syndrome in patients with multiple sclerosis. Neurology (1992) 1.49

Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology (1997) 1.48

Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun (2000) 1.45

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler (2011) 1.42

Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost (1994) 1.23

Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med (1990) 1.13

The prevalence of primary Sjögren's syndrome in a multiple sclerosis population. Ann Neurol (1989) 1.10

Autoimmunity in multiple sclerosis. Neurology (1988) 1.08

A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 0.95

Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol (1998) 0.94

Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler (1999) 0.94

Multiple sclerosis and other immunologic diseases. Acta Neurol Scand (1990) 0.93

Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus (2011) 0.88

Validity of screening tests for Sjögren's syndrome in ambulatory patients with chronic diseases. J Rheumatol (2006) 0.86

Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol (2001) 0.86

Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry (2002) 0.85

Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients. Acta Neurol Scand (2001) 0.84

Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol (2007) 0.82

MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol (2009) 0.82

A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. Mult Scler (2005) 0.81

Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun (2000) 0.81

Antinuclear antibodies in multiple sclerosis. Arch Neurol (1982) 0.79

Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res (2002) 0.78

Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler (2003) 0.78

Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology (1998) 0.77

The interface of multiple sclerosis and antiphospholipid antibodies. Thromb Res (2004) 0.77

No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg Psychiatry (2007) 0.77

Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis. Mult Scler (2000) 0.76

Articles by these authors

Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res (2005) 2.39

"Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. Neurology (2012) 1.94

Fifteen years later: can residential mobility programs provide a long-term escape from neighborhood segregation, crime, and poverty? Demography (2005) 1.90

Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A (2007) 1.76

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54

Effects of Group, Individual, and Home Exercise in Persons With Parkinson Disease: A Randomized Clinical Trial. J Neurol Phys Ther (2015) 1.48

Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction. Somatosens Mot Res (2008) 1.42

Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep (2009) 1.37

Centella asiatica accelerates nerve regeneration upon oral administration and contains multiple active fractions increasing neurite elongation in-vitro. J Pharm Pharmacol (2005) 1.33

Improving the follow-up of positive hemoccult screening tests: an electronic intervention. J Gen Intern Med (2011) 1.21

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol (2009) 1.17

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler (2011) 1.16

Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol (2013) 1.04

Falls requiring medical attention among veterans with multiple sclerosis: a cohort study. J Rehabil Res Dev (2011) 1.02

Activation of the mitochondrial permeability transition pore modulates Ca2+ responses to physiological stimuli in adult neurons. Eur J Neurosci (2011) 1.02

Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs (2002) 1.01

The radiologically isolated syndrome: look (again) before you treat. Curr Neurol Neurosci Rep (2011) 1.01

Immunotherapy and multiple sclerosis: The devil is in the details. Neurology (2010) 0.98

Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients. Mult Scler (2013) 0.95

Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Mol Neurodegener (2012) 0.94

Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res (2004) 0.94

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol (2010) 0.94

A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis (2014) 0.91

Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis. Eur J Neurosci (2012) 0.91

Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology (2007) 0.91

Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis. J Immunol (2003) 0.90

Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol (2011) 0.90

Fingolimod and multiple sclerosis: four cautionary tales. Neurology (2012) 0.90

Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol (2010) 0.89

Predicting falls in people with multiple sclerosis: fall history is as accurate as more complex measures. Mult Scler Int (2013) 0.88

Complementary and alternative medicine in multiple sclerosis: survey of licensed naturopaths. J Altern Complement Med (2004) 0.87

Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences. Neurology (2013) 0.87

Novel method for measurement of fatigue in multiple sclerosis: Real-Time Digital Fatigue Score. J Rehabil Res Dev (2010) 0.87

Mitochondrial calcium and its regulation in neurodegeneration induced by oxidative stress. Eur J Neurosci (2011) 0.87

Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology (2012) 0.84

Complementary and alternative medicine: is there a role in multiple sclerosis? Curr Neurol Neurosci Rep (2006) 0.83

Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front Physiol (2013) 0.83

Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurol Res (2004) 0.83

People with multiple sclerosis use many fall prevention strategies but still fall frequently. Arch Phys Med Rehabil (2013) 0.83

Differences in knowledge, attitudes, beliefs, and perceived risks regarding colorectal cancer screening among Chinese, Korean, and Vietnamese sub-groups. J Community Health (2014) 0.82

Perceived stress in multiple sclerosis: the potential role of mindfulness in health and well-being. J Evid Based Complementary Altern Med (2014) 0.81

Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma (2011) 0.80

New disease-modifying therapies and new challenges for MS. Curr Neurol Neurosci Rep (2012) 0.79

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study. Mult Scler (2013) 0.79

Recent developments in multiple sclerosis therapeutics. BMC Med (2009) 0.79

TINU (tubulointerstitial nephritis and uveitis) syndrome is not usually associated with IgG4 sclerosing disease. Am J Kidney Dis (2012) 0.79

Genetic inactivation of mitochondria-targeted redox enzyme p66ShcA preserves neuronal viability and mitochondrial integrity in response to oxidative challenges. Front Physiol (2012) 0.78

Healing pathways: a program for women with physical disabilities and depression. Rehabil Res Pract (2013) 0.78

Availability of healthy snack foods and beverages in stores near high-income urban, low-income urban, and rural elementary and middle schools in Oregon. Child Obes (2014) 0.78

Frequency-modulation (FM) technology as a method for improving speech perception in noise for individuals with multiple sclerosis. J Am Acad Audiol (2006) 0.78

A randomized pilot study of naturopathic medicine in multiple sclerosis. J Altern Complement Med (2008) 0.77

Remyelination and multiple sclerosis: therapeutic approaches and challenges. Curr Neurol Neurosci Rep (2014) 0.77

Nonmyelin-specific T cells accelerate development of central nervous system APC and increase susceptibility to experimental autoimmune encephalomyelitis. J Immunol (2003) 0.77

Postmarketing adverse drug reactions: A duty to report? Neurol Clin Pract (2013) 0.77

Medical student views on interactions with pharmaceutical representatives. Acad Psychiatry (2012) 0.77

Focal increases of axoplasmic Ca2+, aggregation of sodium-calcium exchanger, N-type Ca2+ channel, and actin define the sites of spheroids in axons undergoing oxidative stress. J Neurosci (2012) 0.77

A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Invest New Drugs (2009) 0.77

Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation. Neuromuscul Disord (2010) 0.76

The radiologically isolated syndrome: is it very early multiple sclerosis? Neurology (2008) 0.76

Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. J Ophthalmic Inflamm Infect (2012) 0.76

The radiologically isolated syndrome revisited: when is it presymptomatic multiple sclerosis? Neurology (2011) 0.75

Reply: To PMID 19798640. Ann Neurol (2010) 0.75

New oral disease-modifying therapies for multiple sclerosis. F1000 Med Rep (2009) 0.75

Depression is a treatable cause of suffering among multiple sclerosis patients and can result in suicide. Neurology (2002) 0.75

The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metab Brain Dis (2014) 0.75

Interruption of natalizumab therapy for multiple sclerosis: what are the risks? Neurology (2011) 0.75

Oral disease-modifying therapies for multiple sclerosis: are we there yet? Curr Neurol Neurosci Rep (2010) 0.75

Retinal Blood Flow Response to Hyperoxia Measured With En Face Doppler Optical Coherence Tomography. Invest Ophthalmol Vis Sci (2016) 0.75

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep (2008) 0.75

MS and bone marrow transplant: Not for most patients. Neurology (2017) 0.75

Anti-NMDA receptor encephalitis with paroxysmal sympathetic hyperactivity: an under-recognized association? Clin Auton Res (2012) 0.75

A group-delivered self-management program reduces spasticity in people with multiple sclerosis: A randomized, controlled pilot trial. Mult Scler J Exp Transl Clin (2017) 0.75

Does interferon beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis? J Neurosci Nurs (2014) 0.75

Early Fever As a Predictor of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury. J Head Trauma Rehabil (2017) 0.75